New drug data could lift shares of this biotechnology stock, Truist says
Biogen could see more upside if it publishes positive results from recent trials linked to kidney and Alzheimer's treatments, Truist Securities says.
Overview
Biogen could see more upside if it publishes positive results from recent trials linked to kidney and Alzheimer's treatments, Truist Securities says.
Source
Originally published at www.cnbc.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.